ACROBiosystems Adjusts Valuation Amid Mixed Financial Indicators and Growth Prospects

ACROBiosystems Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's technical and valuation metrics. The valuation grade has transitioned from attractive to fair, indicating a recalibration of how the stock is perceived in terms of its financial metrics. Key financial indicators reveal a P/E ratio of 67, alongside a price-to-book value of 3.85. The company’s EV to EBIT stands at 94.66, while the EV to EBITDA is recorded at 48.03. Additionally, the PEG ratio is noted at 2.13, and the return on equity (ROE) is at 5.73%. Despite a positive growth in net sales of 26.33% for the quarter ending September 2025, the long-term growth trajectory appears to be less favorable, with an annual growth rate of 22.62% in net sales and an operating profit decline of 2.36% over the past five years. The technical outlook has also seen a shift, moving from bullish to mildly bullish, reflecting mixed signals across various indicators. Overall, the adjustments in ACROBiosystems' evaluation underscore the complexities of its current market position and financial health. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.